Experience during the 1970s in the United States with aminoglycoside resistance among gram-negative bacilli suggested that gentamicin and tobramycin might lose their effectiveness as therapeutic agents because of the widespread development of resistance (4, 7, 13, 15) . Many of these resistant organisms were shown to carry resistance or R plasmids that bore the genetic information for enzymatic resistance and that could be transferred from organism to organism (6, 10, 11, 18 ). An outbreak of this type was initially noted at our institution in 1975, first among Klebsiella species, then among Serratia species, and eventually among multiple other members of the family Enterobacteriaceae (4, 18) . This outbreak persisted into the 1980s and was subsequently found to be due to a unique plasmid or one of its closely related descendants that persisted in the hospital for at least 10 years (10, 11) . Initially, up to 1980, the usage of amikacin was restricted and applied only in cases of gentamicin and tobramycin resistance. However, beginning in 1980, a new policy was instituted in which aminoglycosides were rotated, depending upon resistance in the hospital, using amikacin extensively if gentamicin resistance increased. We have previously reported our experience through 1984 with this practice (5) , and the purpose of this report is to update our experience since 1984 with the rotational use of aminoglycoside antibiotics.
MATERIALS AND METHODS
From April 1980 through March 1990, aminoglycoside usage was continuously monitored from pharmacy records, * Corresponding author. and antibiotic resistance among gram-negative bacilli was monitored from microbiology laboratory records. The observation period was divided into distinct segments (Table 1) on the basis of the predominant aminoglycoside usage during that time, beginning with the period from April to July 1980 (period one), which is the baseline period during which gentamicin and tobramycin usage predominated. This was followed by a period from July 1980 until the end of August 1982 (period two), during which amikacin became the predominant aminoglycoside in use in the hospital. The third distinct period of observation was from September 1982 through the end of August 1983 (period three), a 1-year period during which gentamicin was reintroduced into the institution and was used at a reasonably high level. Beginning in September 1983 amikacin was once again reintroduced as the predominant aminoglycoside and was used through December 1985 (period four). The fifth and final alteration in usage began in January 1986, at which time gentamicin was once again reintroduced to the hospital, but was used at a modest level and gradually increased in percentage of usage over the period from 1986 through 1990 (period five). In late June 1988, patients and personnel moved to a new hospital building, and so resistance data for the new building were tabulated separately. Data were recorded for hospital location and infection site of each resistant organism.
Susceptibilities of gram-negative aerobic bacilli to the aminoglycosides were determined by the broth microdilution method (5) . All aerobic and facultative gram-negative bacilli isolated from specimens submitted to the microbiology laboratory were screened for their susceptibilities to the study drugs. Only the first isolate of a species obtained during each Statistically significant changes in resistance to gentamicin and tobramycin occurred with each change in aminoglycoside policy with the exception of period five (Table 1) . In period three, the reintroduction of gentamicin was rapid and emergence of resistance was also rapid; in period five, with a more gradual introduction of gentamicin and gradual reduction of amikacin usage, no significant rise in gentamicin resistance occurred. Overall, resistance to gentamicin during period five was 5.7%, which was essentially unchanged from that during period four. In contrast to the markedly changing resistance to gentamicin and tobramycin over time, there was no significant change in resistance to amikacin during any of the periods of monitoring, and resistance remained stable at 2.9 to 3.9% throughout the entire study. Resistance to netilmicin was measured only during period five and was 9% for all gram-negative bacilli, largely because of the 35% resistance of P. aeruginosa.
Aminoglycoside usage and percent resistance are shown
RESULTS
Summary data for each of the five study periods are given in Table 1 . Although usage of aminoglycosides in this Medical Center (patient days per month) actually increased from 1980 to 1990, usage declined significantly over the past 5 years compared with usage in the first 5 years of the study ( Fig. 1 ; P < 10-8). Usage of tobramycin has been minimal in the hospital since the original baseline observation period in 1980 and constituted less than 2.5% of all usage after that period. Usage of netilmicin during the entire study was negligible. Hence, the primary aminoglycoside usage was divided between amikacin and gentamicin. The major change to amikacin usage was accomplished by a pharmacy policy requiring approval for use of gentamicin by the infectious disease service throughout periods two and four. The shift back to gentamicin was accomplished by placing both gentamicin and amikacin on open formulary without the need for approval for either one. The institution of a control policy for gentamicin resulted in a marked increase in Table 2 ). This trend toward lower resistance was evident for the year preceding the hospital move (Fig. 2) and continued during the 21 months after the move. The difference between resistance rates in the year prior to the move and the 21 months after moving was also statistically significant (P < 0.05).
Also given in Table 2 (Fig. 2) .
Throughout these changing periods of aminoglycoside usage, no significant increase in resistance to amikacin was observed. This is somewhat remarkable because we have documented within our organism population those bacteria, particularly Serratia spp., which contain the AAC-6' enzyme which is known to inactivate amikacin. Despite the presence of this enzyme in Serratia organisms, no increase and, in fact, a marked decline in the presence of Serratia organisms containing this enzyme was noted during periods of high amikacin use (8) . Some institutions have noted increased resistance to amikacin with increased use of amikacin (2, 12, 17) , while others have noted a decrease or no change in resistance (1, 14) . Pooled data from 14 hospitals that instituted high-level (86%) amikacin usage indicated a small, but statistically significant (P < 0.05), increase in amikacin resistance from 1.4 to 1.7% of 95,000 isolates (5) . None of these hospitals individually detected a significant increase in amikacin resistance, however, an observation similar to our own long experience. Only one organism, P. Number of isolates of all gram-negative bacilli, Pseudomonas aeruginosa, and members of the family Enterobacteriaceae resistant to gentamicin (shaded bars) and amikacin (solid bars) per quarter of study in four hospital services; urology, surgery, medicine, and intensive care units. Note that the scale differs for each group of organisms. appeared to be different from our original index resistance plasmid, because they did not show the presence of the ANT-2" resistance gene when probed with a DNA sequence internal to this gene (3) . Taken together, these data suggest that the original index plasmid is probably no longer present in large numbers of patients or the environment of our institution, but we have not systemically investigated large numbers of gentamicin-resistant organisms since 1988 to confirm this. Most gentamicin resistance at this time is found in P. aeruginosa and has not been associated with any enzymatic inactivation, but it is presumed to be due to a permeability barrier.
Aminoglycoside usage, as measured by patient days, rose from under 2,000 patient days per quarter in 1980 to well over 3,000 patients day per quarter in 1985 (Fig. 1) . Since 1985, however, usage has declined significantly. These changes in aminoglycoside usage occurred as the daily hospital census declined linearly from 590 patients in 1980 to 465 in 1989, the last full year of the study. A declining census could explain the usage decline of the past 5 years, but it does not explain the rise in usage from 1980 to 1985. Substitution of other antimicrobial agents that are active against gram-negative bacilli and less toxic than aminoglycosides is another likely explanation for the recent decline in usage. Most of these alternative agents, such as ceftazidime, ceftizoxime, ceftriaxone, piperacillin, ticarcillin-clavulanate, imipenem-cilastatin, ciprofloxacin, and aztreonam, are on a restricted formulary and require telephone approval by the infectious disease service for use. We do not have accurate data on the usage of these agents in comparison with the usage of aminoglycosides, but we have noted increased requests for approvals for use in elderly patients and those with increased serum creatinine levels. Since the overall decline in aminoglycoside usage occurred almost entirely within period five of the surveillance study, this may have played an additional role in the lack of resistance development during this period of increased percentage of gentamicin usage.
Although the observed changes in aminoglycoside resistance following changes in aminoglycoside usage can only be termed associations and are not proven causes and effects, we remain impressed that there is a relationship between the availability of aminoglycosides within the hospital environment and the emergence of resistance. For these reasons, we have continued to follow our aminoglycoside usage patterns through 1990 and are monitoring resistance to the aminoglycosides by means of monthly susceptibility reports. At this time, it appears the balance we have achieved between the usage of gentamicin and amikacin is associated, in our institution, with an enviably low resistance to all aminoglycosides. Whether such a continued low resistance can be maintained by this usage policy will remain to be seen.
